Europe PEGylated Proteins Market Size, Forecast by 2022-2028

Europe PEGylated Proteins Market Size, Share & Industry Trends Analysis Report By Product & Services, By Type (Colony-stimulating Factor, Interferons, Recombinant Factor VII, Erythropoietin), By End-user, By Application, By Country and Growth Forecast, 2022 - 2028

Published Date: November-2022 | Number of Pages: 96 | Format: PDF | Report ID: KBV-12665

Special Offering: Industry Insights | Market Trends | Highest number of Tables | 24/7 Analyst Support


Get in-depth analysis of the COVID-19 impact on the Europe PEGylated Proteins Market

Market Report Description

The Europe PEGylated Proteins Market would witness market growth of 10.9% CAGR during the forecast period (2022-2028).

The main factors driving the growth are driving the demand for protein-based treatments, along with a boost in research activities for the creation of novel therapeutics and the benefits of PEGylated therapeutic proteins. Other important drivers include the rising incidence of degenerative & chronic diseases such as cancer, rheumatoid arthritis, and kidney disease.

The use of protein-based treatments has grown as a result of advancements in molecular biology engineering and biotechnology. In recent years, it has become quite apparent that there is an ever-increasing demand for recombinant proteins, including enzymes, hormones, growth factors, and monoclonal antibodies, among others.

Due to the therapeutic benefits of specificity and enhanced activity, biologics are now widely available and well-known among the affected community. For instance, the French biotechnology company LFB (Laboratoire Francais du Fractionnement et des Biotechnologies) received approval from the American FDA in April 2020 for a novel treatment for hemophilia.

In Europe, diabetes is growing more prevalent among individuals of all ages as a result of rising overweight and obesity rates, poor diets, and lack of physical activity. According to the World Health Organization, kidney failure accounts for 10 to 20% of cases of death for diabetics and accounts for 50% of deaths from cardiovascular disease (mostly heart disease and stroke). Approximately 60 million people in the European Region—10.3% of males and 9.6% of women over 25—have diabetes.

The Germany market dominated the Europe PEGylated Proteins Market by Country in 2021, and would continue to be a dominant market till 2028; thereby, achieving a market value of $137.6 million by 2028.The UK market is experiencing CAGR of 9.9% during (2022 - 2028). Additionally, The France market would display a CAGR of 11.7% during (2022 - 2028).

Based on Product & Services, the market is segmented into Consumables and Services. Based on Type, the market is segmented into Colony-stimulating Factor, Interferons, Recombinant Factor VII, Erythropoietin and Others. Based on End-user, the market is segmented into Pharmaceutical & Biotechnology Companies, Contract Research Organizations (CROs) and Academic & Research Institutes. Based on Application, the market is segmented into Cancer, Autoimmune Diseases, Hepatitis, Multiple Sclerosis, Hemophilia, Gastrointestinal Disorders and Others. Based on countries, the market is segmented into Germany, UK, France, Russia, Spain, Italy, and Rest of Europe.

Free Valuable Insights: The Global PEGylated Proteins Market will Hit $2.1 Billion by 2028, at a CAGR of 11.3%

The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Merck Millipore (Merck KGaA), Thermo Fisher Scientific, Inc., NOF Corporation, JenKem Technology Co. Ltd., Creative PEGworks, Celares GmbH, Quanta BioDesign, Ltd., Biomatrik, Inc., Iris Biotech GmbH, and Laysan Bio, Inc.

Scope of the Study

Market Segments Covered in the Report:

By Product & Services

  • Consumables
  • Services

By Type

  • Colony-stimulating Factor
  • Interferons
  • Recombinant Factor VII
  • Erythropoietin
  • Others

By End-user

  • Pharmaceutical & Biotechnology Companies
  • Contract Research Organizations (CROs)
  • Academic & Research Institutes

By Application

  • Cancer
  • Autoimmune Diseases
  • Hepatitis
  • Multiple Sclerosis
  • Hemophilia
  • Gastrointestinal Disorders
  • Others

By Country

  • Germany
  • UK
  • France
  • Russia
  • Spain
  • Italy
  • Rest of Europe

Key Market Players

List of Companies Profiled in the Report:

  • Merck Millipore (Merck KGaA)
  • Thermo Fisher Scientific, Inc.
  • NOF Corporation
  • JenKem Technology Co. Ltd.
  • Creative PEGworks
  • Celares GmbH
  • Quanta BioDesign, Ltd.
  • Biomatrik, Inc.
  • Iris Biotech GmbH
  • Laysan Bio, Inc.

Unique Offerings from KBV Research

  • Exhaustive coverage
  • The highest number of Market tables and figures
  • Subscription-based model available
  • Guaranteed best price
  • Assured post sales research support with 10% customization free

Related Reports:

Global PEGylated Proteins Market Report 2022-2028

North America PEGylated Proteins Market Report 2022-2028

Asia Pacific PEGylated Proteins Market Report 2022-2028

LAMEA PEGylated Proteins Market Report 2022-2028

Purchase Report


Special Pricing & Discounts

  • Buy Sections of This Report
  • Buy Country Level Reports
  • Request for Historical Data
  • Discounts Available for Start-Ups & Universities